Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK- Anaplastic Large Cell Lymphoma (ALCL)”

53 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 53 results

Testing effectiveness (Phase 2)Ended earlyNCT02572453
What this trial is testing

Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL

Who this might be right for
Recurrent Anaplastic Large Cell LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Mantle Cell Lymphoma+5 more
National Cancer Institute (NCI) 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT03113500
What this trial is testing

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

Who this might be right for
Adult T-Cell Leukemia/LymphomaAnaplastic Large Cell Lymphoma, ALK-NegativeAnaplastic Large Cell Lymphoma, ALK-Positive+8 more
City of Hope Medical Center 48
Testing effectiveness (Phase 2)Active Not RecruitingNCT02223208
What this trial is testing

Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas

Who this might be right for
Peripheral T-cell Lymphomas (PTCL)PTCL-NOSAngioimmunoblastic T-cell Lymphoma (AITL)+2 more
Fondazione Italiana Linfomi - ETS 89
Testing effectiveness (Phase 2)Looking for participantsNCT07013565
What this trial is testing

Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL

Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-Positive
New York Medical College 20
Testing effectiveness (Phase 2)UnknownNCT01719835
What this trial is testing

CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study

Who this might be right for
Peripheral T-cell Lymphoma NOSAnaplastic Large Cell Lymphoma, ALK-NegativeAngioimmunoblastic T-cell Lymphoma+2 more
Royal Marsden NHS Foundation Trust 87
Testing effectiveness (Phase 2)Study completedNCT01979536
What this trial is testing

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-PositiveAnn Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell LymphomaAnn Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma+1 more
National Cancer Institute (NCI) 137
Testing effectiveness (Phase 2)Looking for participantsNCT04094610
What this trial is testing

Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Who this might be right for
Locally Advanced Solid TumorsMetastatic Solid TumorsLymphoma+1 more
Turning Point Therapeutics, Inc. 75
Testing effectiveness (Phase 2)Ended earlyNCT00082017
What this trial is testing

UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas

Who this might be right for
Lymphoma, Large-Cell, Ki-1Lymphoma, T-Cell
National Cancer Institute (NCI) 20
Early research (Phase 1)UnknownNCT00562068
What this trial is testing

Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma

Who this might be right for
LymphomaSmall Intestine Cancer
Cancer Research UK 30
Testing effectiveness (Phase 2)Ended earlyNCT02462538
What this trial is testing

Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL

Who this might be right for
ALK+ Anaplastic Large Cell Lymphoma
Arbeitsgemeinschaft medikamentoese Tumortherapie 3
Testing effectiveness (Phase 2)UnknownNCT04476459
What this trial is testing

Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

Who this might be right for
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma Grade IIIb+3 more
Huiqiang Huang 33
Early research (Phase 1)Looking for participantsNCT06176690
What this trial is testing

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

Who this might be right for
CD30-Positive Diffuse Large B-Cell LymphomaAnaplastic Large Cell Lymphoma, T Cell and Null Cell TypeAnaplastic Large Cell Lymphoma, ALK-Positive+4 more
Baylor College of Medicine 90
Post-approval studies (Phase 4)UnknownNCT03707847
What this trial is testing

Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL

Who this might be right for
ALK-Positive Anaplastic Large Cell Lymphoma
Mingzhi Zhang 20
Not applicableUnknownNCT03971305
What this trial is testing

A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL

Who this might be right for
MRDMDDLymphoma, Nonhodgkin+2 more
Sun Yat-sen University 300
Not applicableStudy completedNCT02902874
What this trial is testing

Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK +

Who this might be right for
ALCL
Gustave Roussy, Cancer Campus, Grand Paris 185
Not applicableNot Yet RecruitingNCT07467317
What this trial is testing

BV-CHP Real-life and Biological Evidences in Patients With sALCL

Who this might be right for
Anaplastic Large Cell Lymphoma
Fondazione Italiana Linfomi - ETS 100
Not applicableStudy completedNCT03603847
What this trial is testing

Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma

Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-Positive
The Lymphoma Academic Research Organisation 41
Testing effectiveness (Phase 2)Active Not RecruitingNCT02978625
What this trial is testing

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-NegativeAnaplastic Large Cell Lymphoma, ALK-PositiveApocrine Carcinoma+36 more
National Cancer Institute (NCI) 68
Testing effectiveness (Phase 2)Active Not RecruitingNCT03703050
What this trial is testing

Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)

Who this might be right for
Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma
Gustave Roussy, Cancer Campus, Grand Paris 45
Testing effectiveness (Phase 2)UnknownNCT04058470
What this trial is testing

Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma

Who this might be right for
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma Grade IIIb+3 more
Huiqiang Huang 140
Load More Results